Department of Dermatology, Bern University Hospital and University of Bern, Bern, Switzerland.
Dermatology. 2009;219(4):353-6. doi: 10.1159/000252853. Epub 2009 Oct 23.
Nail involvement is known as a common finding in psoriatic patients and represents a significant impact on patients' quality of life. The treatment of nail psoriasis is often challenging, and there is a need for new therapeutic options. Biologicals effective in the treatment of moderate to severe chronic plaque psoriasis may represent a new therapeutic modality for this disease. Adalimumab is a fully human IgG1 monoclonal antibody that binds to tumor necrosis factor alpha with high affinity and specificity.
We report two cases of rapid improvement in nail psoriasis under adalimumab monotherapy with maintained effectiveness despite intermittent treatment as well as long remission after therapy discontinuation.
The marked improvement of our two cases indicates that adalimumab may also help ameliorate nail psoriasis and warrants further controlled studies to establish the effectiveness and therapeutic regimes.
指甲受累是银屑病患者的常见表现，对患者的生活质量有重大影响。指甲银屑病的治疗往往具有挑战性，需要新的治疗选择。对中重度慢性斑块型银屑病有效的生物制剂可能为该疾病提供新的治疗方法。阿达木单抗是一种与人 IgG1 单克隆抗体，具有高亲和力和特异性地结合肿瘤坏死因子-α。
我们报告了两例阿达木单抗单药治疗指甲银屑病的病例，尽管间歇性治疗，但仍迅速改善，且在治疗停止后仍保持疗效并长时间缓解。
我们的两例病例显著改善表明阿达木单抗可能还有助于改善指甲银屑病，需要进一步的对照研究来确定其疗效和治疗方案。
